🔎 Trials Near Me

Home › Diffuse Large B-Cell Lymphoma › Virginia › Charlottesville

Diffuse Large B-Cell Lymphoma clinical trials in Charlottesville, VA

7 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Charlottesville (within about 30 miles). Open a study to see who can join and how to contact the study team.

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

RecruitingPhase 2
  • University of Virginia Cancer Center, Charlottesville
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06649812

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

RecruitingPhase 2
  • University of Virginia, Charlottesville
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT06500273

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

RecruitingPhase 1/2
  • University of Virginia Health System, Charlottesville
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

RecruitingPhase 2
  • University of Virginia Health System, Charlottesville
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT05852717

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

RecruitingPhase 1
  • University of Virginia Cancer Center, Charlottesville
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT06015880

A Study of NX-1607 in Adults With Advanced Malignancies

RecruitingPhase 1
  • University of Virginia, Charlottesville
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT05107674

Diffuse Large B-Cell Lymphoma trials in other cities

Other studies in Charlottesville

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.